•   
  •   
  •   

Politics Drug pricing plan faces resistance from Democrats, underscoring dilemma for the party

04:10  16 september  2021
04:10  16 september  2021 Source:   cnn.com

Afghanistan: Panjshir resistance leader Ahmad Massoud backs truce with Taliban to end weeks of fighting

  Afghanistan: Panjshir resistance leader Ahmad Massoud backs truce with Taliban to end weeks of fighting The leader of a resistance group battling a Taliban offensive in Afghanistan's northern Panjshir Valley said he is in support of clerics in the capital Kabul who have called for an end to the fighting, after a weekend of reported heavy losses. © Ahmad Sahel Arman/AFP/Getty Images Afghan resistance movement and anti-Taliban uprising forces take part in a military training at Malimah area of Dara district in Panjshir province on September 2.

A small group of House Democrats voted against key drug pricing provisions on Wednesday in two separate committee markups, underscoring the challenges the party is facing to stay united as it races to finalize sweeping legislation to expand the nation's social safety net. Democratic resistance to drug pricing plan underscores dilemma for party .

An intraparty fight over drug price controls is threatening to derail Democrats ' dreams of sweeping changes to Medicare, Medicaid and the Affordable Care Act as part of their mammoth social spending package. House Energy and Commerce Chair Frank Pallone (D-N.J.) and his senior aides are racing The centrists’ revolt also sparked a panic with progressive advocacy groups like the Center for Popular Democracy , who on Tuesday blasted out alerts urging their members to call members of Congress and press them to vote for the more aggressive drug pricing bill. The dispute over how aggressive the

A small group of House Democrats voted against key drug pricing provisions on Wednesday in two separate committee markups, underscoring the challenges the party is facing to stay united as it races to finalize sweeping legislation to expand the nation's social safety net.

Kurt Schrader et al. sitting at a table: WASHINGTON, DC - JUNE 23: Representative Kurt Schrader, a Democrat from Oregon, questions witnesses during a hearing of the House Committee on Energy and Commerce on Capitol Hill on June 23, 2020 in Washington, DC. The committee is investigating the Trump administration's response to the COVID-19 pandemic. (Photo by Sarah Silbiger-Pool/Getty Images) © Sarah Silbiger-Pool/Getty Images WASHINGTON, DC - JUNE 23: Representative Kurt Schrader, a Democrat from Oregon, questions witnesses during a hearing of the House Committee on Energy and Commerce on Capitol Hill on June 23, 2020 in Washington, DC. The committee is investigating the Trump administration's response to the COVID-19 pandemic. (Photo by Sarah Silbiger-Pool/Getty Images)

Democratic Reps. Scott Peters of California, Kurt Schrader of Oregon and Kathleen Rice of New York voted against a proposal to allow Medicare to negotiate lower drug prices during a markup in the House Energy and Commerce Committee. With the three "no" votes, the drug pricing section of the larger package the panel was considering came to a tied vote and failed as a result, foreshadowing the problems ahead for Democratic leadership, which can only afford to lose three Democratic votes when the measure is brought to the chamber's floor.

3 Key Divides in Democrats’ Civil War Over the Biden Agenda

  3 Key Divides in Democrats’ Civil War Over the Biden Agenda It’s not just progressives versus moderates.Joe Biden may have less room for error.

The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Wednesday that it is launching a seven-figure ad campaign against the proposals moving through Congress to lower prescription drug prices .&n. "There’s really nothing in the proposal that would allow the government to decide which medications people on Medicare can get." Allowing the secretary of Health and Human Services to negotiate lower drug prices , the center of Democrats ' measures, is extremely popular with voters in polls.

The disputes are particularly troublesome because Democrats , facing a wall of Republican opposition, are pushing through their plan under a special budget process known as reconciliation, which shields it from a filibuster and can pass with a simple majority vote. But their slim margins in both chambers will require almost total Another Democrat and a co-sponsor of that alternative, Representative Kathleen Rice of New York, also said she would vote against the leaders’ plan , which would allow Medicare to negotiate prices for the government and tie acceptable drug prices to those paid in other countries.

But, the setback in the Energy and Commerce Committee does not mean it's the end of the line for the provision, as a similar proposal passed out of the Ways and Means Committee on Wednesday, which means the measure can still make it into the final version of the bill.

Democrats have estimated that the drug pricing provision would raise about $700 billion, which they need to cover the cost of their $3.5 trillion proposal. Without the provision, Democrats would have a significant gap in financing, especially as some in the Senate have argued they want the plan to be fully paid for.

During a Ways and Means Committee markup also on Wednesday, moderate Democratic Rep. Stephanie Murphy of Florida voted against the entire package, which included the proposal to allow Medicare to negotiate drug costs.

Moderate House Democrats threaten drug pricing bill in House panel

  Moderate House Democrats threaten drug pricing bill in House panel Three moderate House Democrats announced that they would vote against their party's legislation to lower drug prices in committee on Tuesday, threatening a defeat for one of Democrats' signature measures. Reps. Kurt Schrader (D-Ore.), Scott Peters (D-Calif.) and Kathleen Rice (D-N.Y.) announced in separate statements on Tuesday that they would vote against the section of Democrats' $3.5 trillion package dealing with lowering drug prices during a markup in the House Energy and Commerce Committee, which is currently ongoing.

— Opposition to the drug price negotiation plan from at least three moderate Democrats is jeopardizing a fragile timeline for getting reconciliation through the House. — The drug lobby fights back by underscoring Covid-19 innovations in a letter and a seven-figure ad buy launching this week. The standoff jeopardizes Speaker Nancy Pelosi’s timeline for moving the social spending package through the House this month — with the expectation that various committees finish markup today. It also doesn’t bode well for the Senate, where Democrats are already at odds over the cost of

Some Democrats are closely allied with the the drug industry itself, and the party at large has not yet coalesced around a single, cohesive platform on pharmaceutical costs. “The Democrats do not have a concise drug plan ,” said Robert Blendon, a Harvard political scientist who has commissioned recent And it’s not just Trump making it tough for the Democrats to gel around a drug pricing message: Unlike other health care issues that split lawmakers on almost perfect partisan lines, some top Democrats are very willing to accept campaign cash from big-name manufacturers and their lobbyists.

In a statement after the vote, Murphy, who has been part of a group of moderates to continue to voice concerns about the sweeping economic spending package, said that there are "spending and tax provisions that give me pause, and so I cannot vote for the bill at this early stage."

Murphy, however, did not signal how she would vote on the overall package, saying she remains "optimistic" that the final product "will be appropriately targeted and fiscally responsible."


Video: Jen Psaki asked about removal of Trump appointees (CNN)

Even though the drug price provision can make it into the final version of the bill, the pushback from moderates over the issue makes clear how difficult it is going to be for Democrats to remain united and pass the final legislation. Senate Democrats, who control only 50 seats, will need to be completely in step to pass the legislation.

Overnight Health Care — Nicki Minaj stokes uproar over vaccines

  Overnight Health Care — Nicki Minaj stokes uproar over vaccines Welcome to Tuesday's Overnight Health Care, where we're following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup.Rap star Nicki Minaj is under scrutiny from many critics for tweeting about her decision not to get the COVID-19 vaccine, and for promoting an unsubstantiated story to her millions of followers."She should be thinking twice about propagating information that really has no basis as except a one-off anecdote," White House chief medical adviser Anthony Fauci told CNN's Jake Tapper. "That's not what science is all about.

It would also limit price increases on some drugs and eliminate loopholes in law dealing with pricing . “Nobody should have to choose between putting food on the table and filling a prescription. Our plan will drastically lower out-of-pocket drug costs for consumers, as Democrats have promised, while we preserve Progressive groups denounced the Democrat split, urging people to call the representatives and urge them to get behind the other plan . “Reps. Peters, Rice, and Schrader are prioritizing drug company profits over lower drug prices for the American people, particularly for patients with chronic

It would also limit price increases on some drugs and eliminate loopholes in law dealing with pricing . “Nobody should have to choose between putting food on the table and filling a prescription. Our plan will drastically lower out-of-pocket drug costs for consumers, as Democrats have promised, while we preserve Progressive groups denounced the Democrat split, urging people to call the representatives and urge them to get behind the other plan . “Reps. Peters, Rice, and Schrader are prioritizing drug company profits over lower drug prices for the American people, particularly for patients with chronic

White House spokesman Andrew Bates said in a statement Wednesday that "the President agrees with Speaker Pelosi that it in order to build an economy that delivers for the middle class and working families -- not just those at the top -- it is critical we empower Medicare to directly negotiate for lower drug prices."

In a sign of tensions over what to include in the massive economic package, Vermont Sen. Bernie Sanders, an independent who caucuses with Democrats, criticized the vote by the trio of Democrats in the Energy and Commerce Committee, saying in a statement that he was "very disappointed."

"I understand that the pharmaceutical industry owns the Republican Party and that no Republican voted for this bill, but there is no excuse for every Democrat not supporting it," Sanders, the chair of the Senate Budget Committee, said.

At issue is a measure that calls for requiring the Health and Human Services secretary to negotiate maximum fair prices of at least 50 and as many as 250 high-cost medications that lack competition, including insulin. The price would be available to Medicare beneficiaries and to individuals enrolled in group health plans. A Congressional Budget Office report has said it could save the federal government $456 billion over a decade.

Centrist Democrats scramble House drug pricing effort

  Centrist Democrats scramble House drug pricing effort The moderates' stand could complicate Democrats’ push to reform a slew of federal health programs as part of their $3.5 trillion bill.Reps. Scott Peters (D-Calif.), Kathleen Rice (D-N.Y.) and Kurt Schrader (D-Ore.) joined Republicans in voting against leadership-backed drug pricing language at the end of a three-day House Energy and Commerce Committee markup of the sweeping package. The 29-29 tie vote meant the provision could not advance.

The House passed a similar bill, also backed by Pelosi, in 2019 by a vote of 230-192. At the time, the speaker had a tough time locking down support from progressives, who complained the bill wasn't aggressive enough.

Democrats have long pushed to reduce drug costs by allowing Medicare to negotiate prices, though some of their Democratic colleagues, as well as GOP lawmakers and the pharmaceutical industry, have opposed it. High drug prices are often among Americans' top health care complaints.

The drug price proposal would also require manufacturers who increase their prices faster than inflation to pay back the excess amount to the federal government, which would benefit enrollees in Medicare and employer-sponsored plans. And it would add a cap to out-of-pocket costs in Medicare drug plans for the first time. Beneficiaries would each pay no more than $2,000.

Additional savings would come from blocking the implementation of a Trump administration regulation that called for changing the rebate system within the drug industry.

Peters and Schrader, saying they would vote against the provision, put forward an alternative proposal that they say would still lower out-of-pocket drug costs.

The pair's proposal aims to lower drug prices through negotiation, but under a narrower set of parameters. It would allow Medicare to negotiate drugs administered in doctors' offices that no longer have exclusivity and for which there is no competition on the market. The HHS secretary could negotiate to secure price concessions of between 25% and 35%.

Drug companies on verge of sinking longtime Democratic priority .
The pharmaceutical industry is on the verge of defeating a major Democratic proposal that would allow the federal government to negotiate drug prices.Speaker Nancy Pelosi (D-Calif.) can afford only three defections when the House votes on a sweeping $3.5 trillion spending package, but Reps. Scott Peters (D-Calif.), Kurt Schrader (D-Ore.) and Kathleen Rice (D-N.Y.) last week voted to block the drug-pricing bill from advancing out of the Energy and Commerce Committee. Rep. Stephanie Murphy (D-Fla.) voted against advancing the tax portion of the legislation in the Ways and Means Committee.

usr: 0
This is interesting!